ESSA Pharmaceuticals EPIX Corporate Presentation June 2022

ESSA Pharmaceuticals is a clinical-stage biotech company developing first-in-class N-terminal domain inhibitors of the androgen receptor for prostate and other androgen-driven cancers. The presentation details the company's lead candidate EPI-7386 in Phase 1 studies, technology licensed from UBC and BC Cancer Agency, and financial position with $181M in cash as of March 2022.